Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study

The goal of this observational study is to learn about cardiac safety monitoring after thoracic radiotherapy in adults with thoracic tumors.

The main question it aims to answer is:

Dose dynamic monitoring of cardiac biomarkers, electrocardiography, echocardiography, peripheral blood immune cell subsets, cytokines, chemokines, lipid profiles, and lipid metabolism markers help identify early clinical or subclinical cardiac changes after thoracic radiotherapy? Are cardiac substructure radiation dose parameters associated with early cardiac safety outcomes? Participants receiving thoracic radiotherapy as part of their regular medical care will complete cardiac safety assessments at the end of radiotherapy, 1 month after radiotherapy, and 3 months after radiotherapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

MACE, Arrhythmia, Pericardial Effusion and Survival Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pericardial Effusion

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients willing to participate the research and sign the informed consent file; Patients aged ≥18 years; KPS≥70; Pathological diagnosis for lung cancer, metastatic lung cancer, esophageal cacner, breast cancer and thymus tumor; Patients received thoracic radiotherapy; No functional heart disease; LVEF≥50%

Exclusion criteria

Patients received thoracic radiotherapy previously; Patients with severe organic and functional disease; Unqualified patients with sufficient reasons; Cannot or no willing to sign the informed consent file

Treatment and study plan

Primary outcomes

cardiac safety

Time frame: From enrollment to the end of thoracic radiotherapy at 3 months

Study contacts

Contact information is provided by the study sponsor or research team.

Yajing Wu, MD

CONTACT

[email protected]

+8618531118178

Sponsors and collaborators

Lead sponsor

Hebei Medical University Fourth Hospital

Other

Collaborators

National Natural Science Foundation of China

Registry information

Official study title

Cardiac Safety Management and Immune Microenvironment Changes in Thoracic Cancer Patients Receiving Different Radiotherapy Modalities: A Prospective Observational Study

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Jun 25, 2026
Registry last updated: Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting